Listen
TROLOVOL (D-penicillamine), chelating agent
TOXICOLOGY - New indication
Opinions on drugs -
Posted on
Aug 02 2017
Reason for request
Extension of indication
Insufficient clinical benefit in the treatment of lead poisoning in the absence of any role in the current therapeutic strategy
- TROLOVOL has Marketing Authorisation for the treatment of lead poisoning.
- In view of a poorly established efficacy of D-penicillamine and of its safety profile, the lack of data about reduction in mortality or morbidity, improvement or quality of life, there is no place in the current therapeutic strategy for lead posoning.
Clinical Benefit
| Insufficient |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
